Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeNon Operating Investment IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Abvc Biopharma (ABVC) Equity Income (2018 - 2025)

Abvc Biopharma (ABVC) has disclosed Equity Income for 6 consecutive years, with -$652979.0 as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Equity Income fell 239.69% year-over-year to -$652979.0, compared with a TTM value of -$803008.0 through Dec 2025, down 87.37%, and an annual FY2025 reading of -$803008.0, down 136.76% over the prior year.
  • Equity Income was -$652979.0 for Q4 2025 at Abvc Biopharma, down from -$54235.0 in the prior quarter.
  • Across five years, Equity Income topped out at -$44917.0 in Q2 2025 and bottomed at -$652979.0 in Q4 2025.
  • Average Equity Income over 3 years is -$133296.6, with a median of -$61060.0 recorded in 2024.
  • The sharpest move saw Equity Income surged 89.66% in 2021, then plummeted 239.69% in 2025.
  • Year by year, Equity Income stood at -$76697.0 in 2021, then plummeted by 150.63% to -$192229.0 in 2024, then tumbled by 239.69% to -$652979.0 in 2025.
  • Business Quant data shows Equity Income for ABVC at -$652979.0 in Q4 2025, -$54235.0 in Q3 2025, and -$44917.0 in Q2 2025.